Urinary minimal residual disease detection predicts recurrence in BCG-unresponsive NIMBC and quantifies molecular response to nadofaragene firadenovec.

Vikram M. Narayan(Emory University), Colin P. Dinney(The University of Texas MD Anderson Cancer Center), Seppo Ylä‐Herttuala(University of Eastern Finland), Vincent T. Bicocca(Convergent Science (United States)), Vincent M. Caruso(Convergent Science (United States)), Sharada Mokkapati(The University of Texas MD Anderson Cancer Center), Alberto Martini(The University of Texas MD Anderson Cancer Center), Nigel Parker(University of Eastern Finland), Côme Tholomier(The University of Texas MD Anderson Cancer Center), Trevor G. Levin(Convergent Science (United States)), David J. McConkey(Johns Hopkins University), David G. Sawutz, Brian C. Mazzarella(Universidad de América), Kevin G. Phillips(Convergent Science (United States))
Journal of Clinical Oncology
January 29, 2024
Cited by 2


Related Papers